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Abstract
Background : Human CD1d-restricted, invariant natural killer T cells (iNKT) are a unique class
of T lymphocytes that recognise glycolipid antigens such as α-galactosylceramide (αGalCer) and
upon T cell receptor (TCR) activation produce both Th1 and Th2 cytokines. iNKT cells expand
when cultured in-vitro with αGalCer and interleukin 2 (IL-2) in a CD1d-restricted manner.
However, the expansion ratio of human iNKT cells varies between individuals and this has
implications for attempts to manipulate this pathway therapeutically. We have studied a panel of
twenty five healthy human donors to assess the variability in their in-vitro iNKT cell expansion
responses to stimulation with CD1d ligands and investigated some of the factors that may influence
this phenomenon.
Results : Although all donors had comparable numbers of circulating iNKT cells their growth rates
in-vitro over 14 days in response to a range of CD1d ligands and IL-2 were highly donor-dependent.
Two reproducible donor response patterns of iNKT expansion were seen which we have called
'strong' or 'poor' iNKT responders. Donor response phenotype did not correlate with age, gender,
frequency of circulating iNKT, or with the CD1d ligand utilised. Addition of exogenous
recombinant human interleukin 4 (IL-4) to 'poor' responder donor cultures significantly increased
their iNKT proliferative capacity, but not to levels equivalent to that of 'strong' responder donors.
However in 'strong' responder donors, addition of IL-4 to their cultures did not significantly alter
the frequency of iNKT cells in the expanded CD3+ population.
Conclusion : (i) in-vitro expansion of human iNKT cells in response to CD1d ligand activation is
highly donor variable, (ii) two reproducible patterns of donor iNKT expansion were observed,
which could be classified into 'strong' and 'poor' responder phenotypes, (iii) donor iNKT response
phenotypes did not correlate with age, gender, frequency of circulating iNKT cells, or with the
CD1d ligand utilised, (iv) addition of IL-4 to 'poor' but not 'strong' responder donor cultures
significantly increased their in-vitro iNKT cell expansion to αGalCer.
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iNKT cells are a minor subpopulation of the human
peripheral blood T cell repertoire. They are members of
the innate lymphocyte subset, which includes natural
killer cells (NK) and γ/δT cells. Both mouse and human
iNKT cells, unlike non-variant NKT, express an invariant
TCR and recognise lipid antigens in association with the
HLA class Ib molecule CD1d. Human iNKT cells express a
combination of Vα24Vβ11 [1] and in mouse Vα14Vβ2,7
or 8 [2]. The precise physiological role of iNKT cells is
uncertain but they are involved in the activation of den-
dritic cells (DC) in response to microbial lipid antigens
and thereby provide a link between innate and adaptive
immune responses to infection [3-5]. They are also
thought to recognise self-lipid antigens presented on
CD1d and hence to play a role in tolerance induction and
the suppression of autoimmunity [6-8]. Conversely, iNKT
cells are involved in cancer immunosurveillance, recog-
nising altered self lipid antigens expressed by malignant
cells and eliminating them at an early stage of transforma-
tion [9].
iNKT cells are universally responsive to αGalCer, a gly-
cosphingolipid antigen derived from the marine sponge
Agelas mauritanius, or to its synthetic analogue KRN7000
[10]. αGalCer binds to the hydrophobic groove of CD1d
and activates all iNKT cells by means of TCR recognition
[9]. Responding cells proliferate and characteristically
release both Th1 and Th2 cytokines.
αGalCer has been reported to promote DC maturation
and subsequent antigen-specific T cell responses via selec-
tive engagement of iNKT cells. DC maturation is then
enhanced via CD40L expression by activated iNKT cells
and via their release of IFNγ resulting in IL-12 production
and HLA upregulation by DC in a positive feed back man-
ner with consequent promotion of antigen presentation
[9].
This adjuvant effect is thought to underlie the observa-
tions made in a number of mouse-models that αGalCer
promotes specific anti-tumour immunity and clearance of
established tumours [11-13]. In turn this has led to the
proposed use of iNKT cell ligands like αGalCer as adju-
vants for human tumour immunotherapy [12,13].
However, iNKT cells are reduced in both number and
activity in patients with certain malignancies [14-19].
Moreover, in-vivo, vaccination with soluble αGalCer leads
to only transient activation of iNKT cells followed by
long-term unresponsiveness [20]. Thus the optimal use of
αGalCer-based immunotherapy for cancer patients is
envisaged to involve infusing αGalCer in-vitro-expanded
autologous iNKT cells followed by αGalCer-pulsed,
tumour antigen-loaded DCs.
Quantitative defects in iNKT cells are predictive of pro-
gression in certain autoimmune diseases. For example,
iNKT cells are reduced in diabetes-prone NOD mice and
increasing iNKT cell numbers by adoptive transfer [21] or
via the introduction of a Vα14-Jβ18 transgene suppresses
subsequent disease progression [22].
All iNKT cells expand when cultured in-vitro with αGalCer
and IL-2 in a CD1d-restricted manner [23] and in-vivo fol-
lowing administration of αGalCer-pulsed DCs [24]. How-
ever, the expansion ratio of human iNKT cells is known to
be highly variable between individuals [25-27].
In this study we have evaluated the iNKT expansion pro-
files of a panel of twenty five healthy human donors to
assess the degree of individual variability on stimulation
with various CD1d ligands. We also sought to define
some of the factors that may influence such donor varia-
tion.
Methods
Patient samples
All donor blood samples were obtained from Queen Eliz-
abeth Hospital, Edgbaston, Birmingham UK, following
patient consent and local Ethics Approval.
Antibodies and flow cytometric analysis
Human iNKT cells were identified using a novel mono-
clonal antibody (clone 6B11) specific for the CDR3 loop
of the human Vα24Jα18 TCR alpha chain which has been
previously reported to specifically identify iNKT cells
[28,29] referred to subsequently as 6B11. Other antibod-
ies comprise CD3-APC, CD4-PerCP and CD8α-FITC (BD
Biosciences). For surface staining, cells were washed with
staining buffer (PBS + 2% FCS), and incubated for 30
mins, on ice in the dark with the relevant antibody com-
binations. Cells were then washed twice with staining
buffer and analysed by flow cytometry (BD Coulter). Data
was collected using a FACS Calibur (BD Biosciences) and
analysed by "Flowjo" flow cytometry software (Tree Star,
Inc).
Glycolipids
αGalCer (C26:0) and PI-3 (C20:2) were synthesised
within GSB's laboratory by PAI, as previously described
[30]. The glycolipids were dissolved in DMSO at a concen-
tration of 100 μg/ml, and diluted into culture medium to
the required final concentration.
iNKT cell proliferation assays to CD1d ligands
Peripheral blood mononuclear cells (PBMC) were iso-
lated from buffy coats by Ficoll density gradient centrifu-
gation. Cells were cultured in RPMI 1640 + L-glutamine (2
mM) + 10% human serum (Lonza) + recombinant
human IL-2 (IL-2) 100 u/ml (Peprotec) in the presence ofPage 2 of 10
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100 or 500 ng/ml or with PI-3 (C20:2) at 100 ng/ml, for
a 14-day culture period. Cell cultures were fed by replace-
ment of half volume media twice weekly with fresh RPMI
supplemented with 1% penicillin and streptomycin, 10%
human serum and IL-2 (200 u/ml). No additional glycol-
ipid was added during feeding of cells. The percentage of
iNKT cells within donor populations were assessed by
flow cytometry performed on days 0 (to allow compari-
son of peripheral iNKT frequency), 7, 10 and 14 days
post-culture. Co-expression of 6B11 (an antibody specific
to the Vα24Jα18 iNKT TCR) and CD3 were used to iden-
tify the iNKT population in each culture [31]. For confir-
mation of iNKT proliferation, PBMC were stained with
CFSE dissolved in DMSO for 10 mins prior to incubation
with αGalCer/IL-2 and proliferation of iNKT was analysed
by dilution of the CFSE signal/6B11+ staining on day 14
post culture. For analysis of subpopulations of iNKT, cells
were surface stained with 6B11-PE, CD3-APC, CD4-PerCP
and CD8α-FITC.
Analysis of effects of age, gender, and peripheral iNKT cell 
frequency
To assess whether donor gender and/or age affected iNKT
expansion, PBMC were isolated from donor blood sam-
ples and iNKT cells allowed to expand in culture with
αGalCer/IL-2 over 14 days for flow cytometric assessment,
as previously described. Peripheral iNKT levels were
assessed by analysing the number of 6B11+ cells within
the CD3+ population of the PBMC of each donor exam-
ined in the study on day 0.
Effects of adding exogenous IL-4 to 'poor' and 'strong' 
responder' iNKT cultures
PBMC were cultured with αGalCer and IL-2 (100 u/ml),
from the blood of identified 'poor' and 'strong' responder
donors as previously described. Exogenous recombinant
human IL-4 (IL-4) (10 ng/ml, Peprotec) was added to the
PBMC cultures at day 0 and the percentage of iNKT cells
present at day 14 post-culture assessed by flow cytometry.
IL-4 was added throughout the 14 day culture period
being added to fresh media (20 ng/ml) prior to feeding of
cells, as previously described.
Statistical Analysis
Data was tested for normal distribution (Shapiro Wilk).
For data with normal distribution Students T tests were
carried out (Excel spreadsheets). For data with non-nor-
mal distribution a non-parametric Man Whitney U test
(SPSS) was performed, which does not assume normal
distribution. P-values < 0.05 were considered as signifi-
cant (95% confidence). All error bars represent the stand-
ard error of the mean.
Results and discussion
iNKT cell proliferative responses to αGalCer are donor-
dependent
Stimulation of PBMC with αGalCer + IL-2 resulted in
expansion of the starting iNKT population over a 14-day
culture period (Fig 1A and see additional file 1). However,
the magnitude of the response was highly variable
between donors with some cultures exhibiting only a
minimal increase in the percentage of iNKT cells above
their starting levels (Fig 1B, see additional file 1). Overall,
a marked dichotomy in the ability of peripheral blood-
Identification of two distinct donor-dependent, iNKT expansion phenotypesFigure 1
Identification of two distinct donor-dependent, iNKT expansion phenotypes. This figure illustrates figure 1A only, 
see additional file 1 for full figure including figures 1A, B, C and D. (A) Representative FACS plots illustrating expansion of 
PBMC-derived iNKT cells (CD3+/6B11+) in response to αGalCer + IL-2 over 7 and 14 days.Page 3 of 10
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was observed (Fig 1B, see additional file 1). Subjects could
be divided into those whose iNKT cells expanded signifi-
cantly over a 14-day culture period (from approx 0.2%
iNKT to 4–18% of the CD3+ population), or those in
whom no or minimal expansion was observed (i.e. from
0.2 to < 2% of the CD3+ population) (Fig 1B, see addi-
tional file 1, n = 25). The expansion rate of the former
being equivalent to a 40–514 fold increase from the start-
ing population while in the latter this equated only to an
expansion rate of < 20 fold. iNKT cells were identified
using a novel monoclonal antibody (clone 6B11) specific
for the CDR3 loop of the human Vα24Jα18 TCR alpha
chain, which has previously been reported to selectively
label iNKT cells [28,29].
The increase in the percentage of iNKT cells within 'strong'
responder cell cultures over 14 days was shown by 5(6)-
carboxyfluorescein diacetate N-succinimidyl ester (CFSE)
staining to result from proliferation of the iNKT cells (Fig
1C, see additional file 1) rather than to their selective sur-
vival within the total CD3+ population. Similarly the lack
of increase in the percentage of iNKT cells within 'poor'
responders was associated with an absence of prolifera-
tion (Fig 1C, see additional file 1). However iNKT cells
were still identifiable within 'poor' responder cultures on
co-staining with 6B11+ and CD3+ following 14 days of
expansion. They were also CFSE positive indicating that
initial peripheral iNKT cells were still present within
'poor' responder cultures but had not divided as well as
those in 'strong' responder cultures in response to αGal-
Cer.
The type of response mounted by a given donor to αGal-
Cer was also stable and highly reproducible over time
when the same subjects were assessed on multiple occa-
sions (Fig 1D, see additional file 1). The data presented
are representative of 2 individuals – 1 'strong' responder
and 1 'poor' responder donor. To date, five different
donors have been assayed on three separate occasions,
and have exhibited a similar consistency in their response
profiles on each occasion.
The results may have clinical implications as several phase
I clinical studies have been carried out in cancer patients
using intravenous αGalCer or αGalCer-loaded DCs, with
limited success [32,17,20,33]. This has been attributed to
a number of different factors including: inefficient deliv-
ery of αGalCer or αGalCer-loaded DCs to the tumour site,
the low numbers of peripheral iNKT cells found in cancer
patients, or to the effects of various pre-treatment drugs
on iNKT and/or their CD1d antigen-presenting cells [18].
However, our results suggest that the donor's inherent
iNKT response phenotype may also affect their clinical
response. By understanding how iNKT cell expansion can
be manipulated in both response phenotypes it may
prove possible to greatly improve the effectiveness of
αGalCer as an immunotherapeutic adjuvant. Moreover by
understanding what factors regulate iNKT cell growth in-
vitro it may prove possible to manipulate their expansion
in 'poor' responder cancer patients to improve the effec-
tiveness of using autologous iNKT cell infusion as an
adjunct to DC immunotherapy.
Analysis of iNKT subpopulations in response to αGalCer
The relative percentages of the three known iNKT cell sub-
populations (i.e. CD4+, CD8+ and CD4-CD8- (double neg-
ative, DN)) were analysed before and after expansion with
αGalCer (Fig 2A and see additional file 2). The study was
undertaken to determine whether the in-vitro conditions
used to expand the iNKT cells altered or promoted the
proliferation of any particular iNKT subset. After 14 days
in culture, all 3 subsets were still identifiable in the result-
ant population. However the expanded CD4+ subset rep-
resented a higher proportion of the total iNKT population
(70%) as compared with their peripheral levels (approxi-
mately 60% of the total iNKT population). In contrast the
expanded DN iNKT subset represented a lower proportion
of the total iNKT population (<5%) as compared with
their peripheral levels (approximately 20% of the total
iNKT population) (Fig 2A and see additional file 2).
Hence CD4+ cells were the predominant phenotype in
both the starting and expanded iNKT cell populations.
This is consistent with the findings of Lin and colleagues
who observed that in the presence of IL-2 the majority of
iNKT cells that responded to αGalCer were CD4+ [34].
Thus following stimulation of donor PBMC with a combi-
nation of αGalCer + IL-2 all three subpopulations of iNKT
cells were still present and identifiable.
iNKT cells expand to different CD1d ligands
Interest in the potential to manipulate iNKT cells for ther-
apeutic purposes has been aroused since the demonstra-
tion that αGalCer could induce iNKT cell activation,
proliferation and secretion of Th1 and Th2 cytokines. The
development of multiple glycolipid analogues with differ-
ent capacities to stimulate iNKT cells has also increased
their potential therapeutic utility [30,35]. We therefore
studied the kinetics of iNKT cell proliferative responses in
PBMC cultures derived from 'strong' and 'poor' responsive
donors to both αGalCer (C26.0) and to its analogue PI-3
(C20:2) (Fig 2B, see additional file 2). The results show
that for each donor the kinetics of their iNKT cell prolifer-
ative response was similar to both analogues (Fig 2B, see
additional file 2, n = 6). The expansion kinetics of two
'strong' responders (Fig 2Bi &2Bii, see additional file 2)
and two 'poor' responders (Fig 2Biii &2Biv, see additional
file 2) are illustrated. The fact that the same donor-
dependent response phenotype was observed with
another CD1d ligand PI-3, which contains a shorter, diun-Page 4 of 10
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proliferation is pre-programmed and not ligand-depend-
ent. PI-3 was used because it is a potent human iNKT cell
antigen, which, unlike αGalCer promotes Th2-biased
rather than Th1 responses in-vitro and in-vivo in mice
[7,9]. Thus, although different CD1d ligands have been
reported to influence the cytokine profiles of iNKT cells
[6,7] we did not observe any related effect on iNKT cell
expansion efficiency. The findings suggest that donor-
dependent factors are more critical than specific glycoli-
pid/CD1d/TCR interactions in determining the degree of
in-vitro iNKT cell proliferative responses.
Effects of αGalCer concentration on iNKT cell expansion
A titration of αGalCer was performed to determine
whether the concentration of the CD1d ligand affected
subsequent iNKT cell proliferation. iNKT expansion
assays were set up to determine the effects of different con-
centrations of αGalCer (i.e. 500, 100 and 10 ng/ml),
using cells derived from previously defined 'strong'
responder donors (Fig 2C, see additional file 2, n = 3). 100
ng/ml of αGalCer, the dose cited in the literature for most
iNKT cell functional studies, elicited the maximum iNKT
proliferative response [9] (Fig 2C, see additional file 2).
Hence 100 ng/ml was used for all further iNKT cell expan-
sion studies. However, titration of the dose of αGalCer
against cells derived from a 'poor' responder donor did
not unmask a proliferative response at either lower or
higher αGalCer concentrations (results not shown) sug-
gesting that the iNKT cell response phenotypes identified
in this study were not dependent on the concentration of
the CD1d ligand used.
Assessment of peripheral levels of iNKT, donor age and 
gender on iNKT cell expansion phenotype
The relationship, between the proportions of iNKT cells in
donor peripheral blood and the functional capacity of the
iNKT's to expand has not been previously determined.
iNKT cell proliferative responses – Effects of iNKT cell subsets, different CD1d ligands and aGalCer concentrationFigure 2
iNKT cell proliferative responses – Effects of iNKT cell subsets, different CD1d ligands and aGalCer concentra-
tion. This figure illustrates figure 2A only, see additional file 2 for full figure including figures 2A, B, and C. (A) Percentage of 
iNKT subpopulations in the total peripheral iNKT cell population and expanded iNKT cell population after 14 days in culture 
with αGalCer + IL-2 (n = 3 +/- standard error of the mean).Page 5 of 10
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ing frequency of iNKT cells within the initial non-adher-
ent CD3+ lymphocyte population of both 'strong' and
'poor' responder donors might explain their different
expansion responses. Analysis of human iNKT cells is par-
ticularly demanding since their frequency among periph-
eral blood T cells is relatively low ranging from < 0.01–
1.1% of the total CD3+ population, with a mean of
approximately 0.2% [36]. No discernable differences were
observed in the percentage of the starting iNKT cell popu-
lations between the different responder donor pheno-
types (Fig 3A and see additional file 3), with 'strong'
responder peripheral frequencies ranging from 0.02–
0.3% (average 0.14%, n = 10) and 'poor' responder fre-
quencies from 0.05–1.07% (average 0.2%, n = 15), indi-
cating that the initial numbers of iNKT cells in the blood
does not determine subsequent iNKT cell expansion effi-
ciency (Fig 3A and see additional file 3). In support of this
finding we observed both poor expansion of iNKT cells in
donors with relatively high peripheral levels of iNKT cells
and conversely strong expansion of iNKT cells in donors
with relatively low peripheral levels of iNKT cells (Fig 3B,
see additional file 3). These findings are consistent with
Crough and colleagues who also failed to observe any
relationship between the iNKT cell percentage in healthy
donors and the degree to which their iNKT cells expanded
in culture to αGalCer [26]. However, it is thought that the
low number of circulating iNKT cells in cancer patients
does contribute to their lack of immune reactivity to αGal-
Cer vaccination [17] as immune activation was observed
in only those patients who had relatively normal pre-
treatment, peripheral iNKT cell numbers [17].
Previous studies have suggested that differences in iNKT
cell proliferation efficiency are associated with the age of
the donor [37,38,26] reflecting presumably either a reduc-
tion in their proliferative capacity, clonal exhaustion or
reduced thymic output. Consistent with these latter
Donor iNKT response phenotypes are not associated with peripheral iNKT levels, donor age or genderFigure 3
Donor iNKT response phenotypes are not associated with peripheral iNKT levels, donor age or gender. This fig-
ure illustrates figure 3A only, see additional file 3 for full figure including figures 3A, B, C and D. (A) Comparison of peripheral 
iNKT cell levels between 'strong' and 'poor' iNKT responsive donor groups (n = 15 'poor' and n = 10 for 'strong' +/- standard 
error of the mean).Page 6 of 10
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cell proliferative response with age with a reduction in the
frequency of iNKT (day 14) was observed in older donors
(Fig 3C, see additional file 3). However no significant cor-
relate between the two was identified (n = 20, R2 = 0.11)
and both 'strong' and 'poor' response phenotypes were
still discernable in both young and elderly donors (Fig 3C,
see additional file 3).
As there have been no previous reports on whether gender
effects iNKT cell expansion the response phenotypes of a
cohort of eleven male and eight female cell donors were
assessed (Fig 3D, see additional file 3). Both 'strong' and
'poor' iNKT responders were identified within each gen-
der group (Fig 3D, see additional file 3) with average iNKT
cell frequencies of 4.78% and 3.45% (P = 0.71) respec-
tively by day 14, suggesting no major bias between males
and females in their iNKT response phenotypes to αGal-
Cer. However, there was an observed trend towards
greater numbers of low responders amongst female
donors, which merits further investigation on larger
donor cohorts.
IL-4 promotes iNKT cell expansion in 'poor' but not in 
'strong' responders
A recent study in mice has reported that exogenous IL-4
augments iNKT cell proliferation early in the culture
period of poor responsive strains whereas IFNγ inhibited
iNKT cell proliferation suggesting that it is the ratio of IL-
4 and IFNγ, which is important in defining iNKT cell
expansion [39]. Thus we investigated whether addition of
exogenous IL-4 could induce stronger iNKT cell prolifera-
tive responses in PBMC cultures derived from 'poor'
responder donors. Addition of recombinant human IL-4
(10 ng/ml) to 'poor' responder donor cultures increased
iNKT cell expansion from approximately 1.4% to 3.6% of
the total CD3+ population over 14 days (n = 4, p = 0.04)
(Fig 4A and see additional file 4). Thus IL-4 contributes to
the donor-dependent heterogeneity observed in iNKT
expansion to αGalCer. Interestingly however addition of
IL-4 (10 ng/ml) to 'strong' responder donor PBMC cul-
tures did not promote iNKT cell proliferation. In fact, IL-4
appeared to reduce the frequency of iNKT cells in the
CD3+ population following 14 days culture, but this affect
was not significant (Fig 4B, see additional file 4).
The ability of IL-4 to promote iNKT cell expansion in
'poor' responder cultures may reflect the fact that GATA-3
has been reported to be critical for their peripheral devel-
opment, function and survival [40] although iNKT matu-
ration is reportedly controlled by the TH1 transcription
factor T-bet [41]. In addition, immature neonatal iNKT
cells have a greater ability to proliferate compared with
more mature iNKT cells [37,42]. In mice, cytokine analy-
sis of the developmental stages of iNKT cells have revealed
a TH2 to TH1 conversion, suggesting that the functions of
iNKT cells may be developmentally controlled [42].
Therefore 'poor' responder donors may prove to have
fewer circulating immature iNKT cells than 'strong'
responder donors. However, if exogenous IL-4 selectively
expands immature iNKT cells, the lack of expansion of
iNKT in 'poor' responders to αGalCer may be attributable
to a greater number of non-responsive immature cells in
such individuals. Support for this comes from the fact that
adult, as opposed to neonatal iNKT cells, are oligoclonally
expanded [43], which results in increased numbers of
iNKT cells after birth in mice [44] and higher numbers of
iNKT cells in adult blood compared with cord blood in
humans [37]. The latter reports suggest that mature iNKT
cells continue to expand after birth presumably in
response to stimulation by self- and/or environmental
antigens presented on CD1d and exist as chronically acti-
vated cells. Whether IL-4 and/or IFNγ production or the
overall balance of these two opposing cytokines is respon-
sible for the inter-individual differences observed in this
study remains to be determined.
Conclusion
We detected marked but reproducible donor-dependent
differences in the expansion of blood iNKT cells in
response to in-vitro culture with αGalCer and IL-2. Indi-
vidual donors could be classified either as 'strong' or
'poor' responders in terms of their relative iNKT expan-
sion efficiencies. The differences in the two response phe-
notypes could not be explained by peripheral levels of
iNKT, the age or sex of the donor, or to the type or concen-
tration of the CD1d ligand used. However, reduced iNKT
proliferative responses were observed in older donors but
not to a significant degree. Expansion in-vitro of iNKT cells
derived from 'poor' responder donors was augmented by
addition of exogenous IL-4 to the cell cultures. The results
suggest that individual donor iNKT cell response pheno-
types may be associated with inherent early differential
production of IL-4 and/or other Th2 cytokines within the
cell cultures.
The inherent differences observed in iNKT cell responses
between individuals, could potentially influence their sus-
ceptibility to diseases in which iNKT cells are implicated,
including autoimmune diseases, malignancies and infec-
tions. The results also suggest that the efficacy of immuno-
therapy with αGalCer/DC-based vaccines may depend
upon the recipients' inherent iNKT cell response pheno-
type. Reconstitution of cancer patients exhibiting a 'poor'
iNKT response phenotype with cytokine-induced, in-vitro
expanded, autologous iNKT cells may then help to boost
their subsequent response to immunotherapy with αGal-
Cer/DC-based vaccines.Page 7 of 10
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and 14 days. (B) Donor response profiles illustrating two distinct iNKT 
cell proliferation phenotypes to αGalCer + IL-2 over 14 days (n = 25). 
(C) Representative CFSE dilution profiles of PBMC-derived iNKT cells 
from a 'strong' and a 'poor' αGalCer responder donor (n = 6, for each phe-
notype), (D) Reproducibility of individual donor iNKT response pheno-
type to αGalCer expansion over 14 days from PBMC – illustration of 
iNKT cell responses obtained in one 'strong' and one 'poor' responder 
donor, each tested on 3 separate occasions.
Click here for file
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Effects of exogenous IL-4 on expansion of iNKT cells in 'poor' and 'strong' responder donorsFigure 4
Effects of exogenous IL-4 on expansion of iNKT cells in 'poor' and 'strong' responder donors. This figure illustrates 
figure 4A only, see additional file 4 for full figure including figures 4A and B. (A) Levels of PBMC-derived iNKT cells from 'poor' 
responder donors after 14-days of culture in the presence of: (i) vehicle (DMSO) + IL-2, (ii) αGalCer + IL-2, or (iii) αGalCer + 
IL-2 + IL-4 (n = 4, +/- standard error of the mean).Page 8 of 10
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